Value of Medical Innovation


Because Patients Can’t Wait®, BioNJ’s mission is to bolster medical innovation and New Jersey’s life sciences ecosystem. The discovery and development of new therapies and cures allow Patients to live longer, healthier, more productive lives – benefiting the entire healthcare system, New Jersey’s economy and society as a whole.

BioNJ advocates on behalf of our Members to ensure that government continues to invest in the research and development of future medical innovation and that medicines are accessible to Patients in need. We are actively engaged with Patients and Patient advocacy organizations, so that the voice of the Patient and his or her family has an even stronger presence and greater impact in our community.

The medical innovation being developed by our companies is drastically improving the way health care is delivered by saving lives and reducing costly institutional care, physician visits and invasive medical procedures.1

  • Oncology – U.S. cancer survivors have more than doubled to 14.5 million since 1990.
  • Hepatitis C – A once incurable disease now has cure rates above 90%.
  • HIV/AIDS – Once a death sentence, it’s now a chronic manageable condition.
  • Childhood Cancer – 83% of children with cancer now survive, compared to 58% in 1970.
  • Vaccines – More than 730,000 children’s lives have been saved in the last 20 years in the United States because of advances in vaccines.

The Value of Medical
Innovation: The Patients Voice

Because, Patients Can’t Wait®
And, “Time is Precious”

Quick Facts on the Value of Medical Innovation

Click here for a primer on the Value of Medical Innovation and Drug Pricing.


Understanding Drug Pricing

Three reasons the Administration should abandon its International Pricing Index proposal

Click here for a helpful video on “Understanding Step Therapy.”

What Patients Think About Step Therapy

Industry Voices: We Need to Move from Patient-Centered Outcomes to Patient-Centered Values

Click here for BIO’s “Understanding Your Drug Costs: Follow the Pill” Video

Click here for BIO’s “Why Are Patients Facing Higher Costs When They Go to the Pharmacy?”

Click here for BIO’s President and CEO Jim Greenwood’s Interview on Drug Pricing

“Balancing the Innovation Premium With the Quality of Health Care in the U.S.”

“Improving the next generation of drugs through patient-centric design for clinical trials”

“The 2010s were a decade of drug breakthroughs”

1Sources: Alzheimer’s Assoc., American Cancer Society, Biotechnology Innovation Organization, CDC, Celgene, FDA, IMS Institute for Healthcare Informatics, NCI, PhRMA, Truven Health Analytics, Tufts CSDD, et al.